title: Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial.
abstract: BACKGROUND
  This study examined the effects of peretinoin, an acyclic retinoid, on the survival of patients with hepatitis C virus-related hepatocellular carcinoma (HCC) who had completed curative therapy and participated in a randomized, placebo-controlled trial.
  
  
  METHODS
  This study was an investigator-initiated retrospective cohort study. Subjects were all patients who were administered the investigational drug (peretinoin 600 mg/day, peretinoin 300 mg/day, or placebo) in the randomized trial. Survivals between the groups were compared using the log-rank test, and hazard ratios were estimated by Cox regression.
  
  
  RESULTS
  Survey data were collected from all patients (n = 392) who participated in the randomized trial, all of whom were then divided into the peretinoin 600 mg/day (n = 132), peretinoin 300 mg/day (n = 131), and placebo (n = 129) groups. At the median follow-up of 4.9 years, 5-year cumulative survival rates for patients in the 600 mg/day, 300 mg/day, and placebo groups were 73.9, 56.8, and 64.3 %, respectively. Comparison of overall survival among patients classified as Child-Pugh A revealed that survival of the 600 mg/day group (n = 105) was significantly longer than that of the placebo group (n = 108) (hazard ratio 0.575, 95 % CI 0.341-0.967; P = 0.0347).
  
  
  CONCLUSIONS
  Administration of 600 mg/day peretinoin to patients with hepatitis C virus-related HCC who have completed curative therapy may improve survival for those classified as Child-Pugh A, for whom liver function is relatively stable.
authors.affiliation: Shimonoseki Kohsei Hospital, Kamishinchi-Machi 3-3-8, Shimonoseki, Yamaguchi, 750-0061, Japan, icb68895@nifty.com.
authors.forename: Kiwamu
authors.initials: K
authors.lastname: Okita
authors.forename: Namiki
authors.initials: N
authors.lastname: Izumi
authors.forename: Kenji
authors.initials: K
authors.lastname: Ikeda
authors.forename: Yukio
authors.initials: Y
authors.lastname: Osaki
authors.forename: Kazushi
authors.initials: K
authors.lastname: Numata
authors.forename: Masafumi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Norihiro
authors.initials: N
authors.lastname: Kokudo
authors.forename: Kazuho
authors.initials: K
authors.lastname: Imanaka
authors.forename: Shuhei
authors.initials: S
authors.lastname: Nishiguchi
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kondo
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nishigaki
authors.forename: Susumu
authors.initials: S
authors.lastname: Shiomi
authors.forename: Kazuomi
authors.initials: K
authors.lastname: Ueshima
authors.forename: Norio
authors.initials: N
authors.lastname: Isoda
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Karino
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Kudo
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Tanaka
authors.forename: Shuichi
authors.initials: S
authors.lastname: Kaneko
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Makuuchi
authors.forename: Takuji
authors.initials: T
authors.lastname: Okusaka
authors.forename: Norio
authors.initials: N
authors.lastname: Hayashi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ohashi
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Kumada
mesh_terms: D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D008297:Male; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic; D012176:Retinoids / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D016588:Anticarcinogenic Agents; D012176:Retinoids; C487689:(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid